Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn more about a drug called Vorinostat (an experimental
drug) in combination with chemoradiation. The intention of this study is to learn if this
drug is safe for the participants and whether this drug with chemoradiation is able to
further increase the clinical efficacy of chemoradiation which is approved therapy for your
tumor condition. The main question it aims to answer is: How may Vorinostat interact with
standard chemotherapy and radiation therapy in head and neck cancer? Participants will be in
either one of two study groups: Group 1 will receive standard chemoradiation, while group 2
will receive the study drug (Vorinostat) as a pre-treatment, followed by standard
chemoradiation.